Cannabinoids for Everyday Health
The BayMedica biosynthetic production method is designed to deliver natural cannabinoids like CBC, CBDV and THCV that are identical to those found in hemp and Cannabis. We have produced more than 20 natural cannabinoids using various manufacturing technologies. Unlike “extracted” cannabinoids, BayMedica cannabinoids are “pharmaceutical-grade” because they are made and purified by a proprietary process that is the same each and every time. Our Prodiol cannabinoids are available as bulk ingredients for use in a wide variety of consumer applications including nutraceuticals, cosmetics and animal-health. Our cannabinoids can be combined in precise ratios to produce Defined SpectrumTM formulations with synergistic, so-called, entourage effects.
BayMedica is able to deliver natural cannabinoids like CBC, CBDV and THCV that are identical to those found in hemp or marijuana, but through a clean, consistent and reliable method.
Our Prodiol cannabinoids are “pharmaceutical-grade” and bioidentical to the compound found in the plant. Prodiol cannabinoids can be custom formulated by manufacturers that produce products for variety of applications including supplements, nutraceuticals, functional food & beverages, cosmetics and animal-health.
BayMedica’s flagship product Prodiol CBC is available in bulk for consumer applications. We lead the industry in the manufacturing scale of CBC with up to 200kg batch sizes and an ability to scale to metric ton quantities.
Cannabichromene (CBC) is non-intoxicating, non-psychoactive cannabinoid that is believed to function by binding the CB2 receptor as well as the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1). The result of engaging these receptors is increased levels of natural endocannabinoids that are known to have positive effects on many body systems.
Cannabidivarin (CBDV), is a non-psychoactive compound found in C. sativa, but unlike cannabidiol (CBD), CBDV is produced in very small amounts in hemp. CBDV has been shown to act through binding of various receptors including the ankryin-type receptor TRPA1 and vanilloid-type, TRPV1 and TRPV2 receptors. Like other CB2 agonists, CBDV is believed to produce a number of positive effects by engaging the Endocannabinoid System.